drugset
drugset / Trial / NCT02954406

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

NCT02954406 ↗

Phase 1 Terminated 43 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.

Timeline

Start
2017-03-05
Primary completion
2020-07-27
Completion
2020-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 90 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Ibrutinib Small molecule 560 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject mivavotinib Small molecule 40 mg Oral
Subject mivavotinib Small molecule 60 mg Oral
Subject mivavotinib Small molecule 80 mg Oral
Subject mivavotinib Small molecule 100 mg Oral

Indications

non-Hodgkin lymphoma